Glycosyl transferase mutant and application of glycosyl transferase mutant in in-vitro enzyme catalysis production of various glycoside compounds

By developing the glycosyltransferase mutant VcUGT1, using multiple glycosyl donors to catalyze the synthesis of flavonoid glycosides, the problems of low catalytic efficiency and environmental pollution of wild-type enzymes are solved, and the efficient and diverse production of flavonoid glycosides is achieved, suitable for biological use Natural drug development in the pharmaceutical field.

CN118909995AActive Publication Date: 2024-11-08ZHEJIANG UNIV

Patent Information

Application Number
CN202411078387.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-07
Publication Date
2024-11-08
Estimated Expiration
2044-08-07

AI Technical Summary

Technical Problem

The prior art When preparing flavonoid glycoside compounds, the catalytic efficiency of wild-type UDP-glucosyltransferases is low, which limits the variety of flavonoid glycoside compounds and the application in the field of biomedical diseases. In addition, the traditional methods have environmental pollution and high cost. question.

Method used

A glycosyltransferase mutant VcUGT1 was developed to introduce specific amino acid mutations (S14G-F366H-S367G) with multiple glycosyl donors (such as UDP-glucose, UDP-galactose, UDP-N-acetylglucose amines and UDP-xylose) catalyze the synthesis of flavonoid glycosides, improving catalytic activity and product diversity.

Benefits of technology

The mutant VcUGT1 significantly improves the yield and variety of flavonoid glycosides, reduces production costs, meets the requirements of green and environmental protection, and provides more natural drug choices for the biomedical field.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909995A_ABST
    Figure CN118909995A_ABST
Patent Text Reader

Abstract

The invention provides a glycosyl transferase mutant and an application of the glycosyl transferase mutant in in-vitro enzyme catalysis production of various glycoside compounds, and belongs to the technical field of novel catalytic enzymes. The invention provides a glycosyl transferase VcUGT1 mutant, and the mutant can be used as a biocatalyst and can efficiently utilize a plurality of different types of glycosyl donors to generate corresponding glycoside products, such as apigenin 7-O-glucoside, apigenin 7-O-galactoside, apigenin 7-O-N-acetylglucosamine and apigenin 7-O-xyloside. Therefore, the mutant can increase variety diversity of flavonoid glycoside compounds, and is of great significance to establishment of a natural drug library and drug screening.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of novel catalytic enzymes, and specifically relates to a glycosyltransferase mutant and its application in in vitro enzyme catalysis to produce a variety of glycoside compounds. Background Art

[0002] Flavonoid glycosides are a class of plant secondary metabolites that are widely present in nature. Flavonoid glycosides are derivatives of chromanes with a C6-C3-C6 basic skeleton, and form a variety of flavonoid types according to the oxidation level and substituent differences at different positions. Sugar substituents are divided into O-glycosides and C-glycosides according to the glycoside chain type. The most common O-glycoside form is formed by connecting the hydroxyl group on the aglycone to the sugar donor, while C-glycoside is formed by connecting the sugar part to the aglycone through a carbon-carbon bond. Most of the sugar-active donors are sugar-containing compounds activated by uridine diphosphate (UDP), including UDP-glucose, UDP-galactose, UDP-glucuronic acid, UDP-N-acetylglucosamine, UDP-rhamnose, UDP-xylose and UDP-arabinose. Among them, UDP-glucose is a typical donor, and its glycosyltransferase is called UDP-glucosyltransferase (UDP-glycosyltransferases, UGTs). When different glycosyl donors are combined with flavonoid aglycones, their water solubility and chemical stability are significantly improved. On the other hand, glycosyl donors not only play an important role in the structural diversity of flavonoids, but also have an important impact on their biological activity.

[0003] Apigenin, also known as apigenin, is a flavonoid compound with multiple biological activities and is widely distributed in various vegetables, fruits and melons. Studies have shown that apigenin mostly exists in a stable glycosylated form, and different sugar donors give it higher and wider biological activities. For example, apigenin-7-O-glucoside inhibits starch synthase activity in a dose-dependent manner; apigenin-7-O-galactoside exhibits good antioxidant and anti-tumor activities, while apigenin-7-O-xyloside has certain antibacterial activity.

[0004] At present, the preparation of flavonoid glycosides containing different glycosyl donors mainly includes: 1) Plant tissue extraction method is the most commonly used preparation method due to its relatively simple process flow and high separation effect. However, this method is greatly limited by geographical, environmental factors and plant growth cycle, and a large amount of organic waste will be generated during the separation and purification process, which cannot meet the requirements of green environmental protection and sustainability. In addition, the content of most target flavonoid glycosides in plant tissues is extremely low, and the production cost is very high. 2) Chemical synthesis method is aimed at flavonoid glycoside compounds that are difficult to separate or have a low content in plant tissues, but traditional chemical synthesis methods require complex protection and deprotection steps, and harmful chemicals will be produced in the middle, so it cannot meet the requirements of large-scale preparation. 3) The use of UGTs to biosynthesize flavonoid glycoside compounds with different glycosyl donor types has attracted much attention due to its simple operation, low cost, and green environmental protection, and has also developed into the most important means of preparing flavonoid glycoside compounds.

[0005] UGTs can be used to directly synthesize flavonoid glycosides using different flavonoid aglycones as substrates by using active glycosyl donors. However, most wild-type UGTs in nature can only use a single type of UDP-sugar as a glycosyl donor, and the catalytic efficiency is low, which greatly restricts the breadth of flavonoid glycoside sugar donors, thereby limiting the diversity of flavonoid glycoside compounds and their application in the biomedical field. Therefore, increasing the glycosyl diversity of flavonoid glycosides through protein engineering technology is an effective way to promote the development of natural drugs. Summary of the invention

[0006] The present invention provides a glycosyltransferase mutant and its application in in vitro enzymatic production of various glycoside compounds. The glycosyltransferase mutant can utilize various glycosyl donors to exert in vitro enzymatic catalysis to synthesize multi-donor type flavonoid glycoside compounds.

[0007] The present invention provides a glycosyltransferase VcUGT1 mutant, the amino acid sequence of which is shown in any one of the following: (a) SEQ ID No. 1;

[0008] (b) has a homology of more than 50% with (a), and the 14th amino acid is glycine, the 366th amino acid is histidine, and the 367th amino acid is glycine.

[0009] The present invention provides a gene encoding the glycosyltransferase VcUGT1 mutant.

[0010] Preferably, the encoding gene includes the nucleotide sequence shown in SEQ ID No.2.

[0011] The present invention also provides biological materials comprising the above encoding gene.

[0012] Preferably, the types of biological materials include recombinant expression vectors and recombinant expression hosts.

[0013] Preferably, the basic backbone vector of the recombinant expression vector includes a eukaryotic expression vector or a prokaryotic expression vector;

[0014] The host cell of the recombinant expression host includes bacterial cells, fungal cells or plant cells.

[0015] The present invention also provides the use of the above biological material in preparing the above glycosyltransferase VcUGT1 mutant.

[0016] The present invention also provides the use of the glycosyltransferase VcUGT1 mutant prepared by using the above biological material in the in vitro enzyme-catalyzed production of flavonoid glycoside compounds.

[0017] The present invention also provides a method for producing flavonoid glycoside compounds by enzyme catalysis in vitro, comprising taking apigenin as a substrate acceptor, utilizing the above-mentioned glycosyltransferase VcUGT1 mutant or the glycosyltransferase VcUGT1 mutant prepared by utilizing the above-mentioned biological material as an enzyme catalyst, catalyzing a glycosylation reaction of a glycosyl donor, and preparing flavonoid glycoside compounds.

[0018] Preferably, the glycosyl donor comprises at least one of the following: UDP-glucose, UDP-galactose, UDP-N-acetylglucosamine and UDP-xylose.

[0019] Beneficial effects: The present invention provides a glycosyltransferase VcUGT1 mutant, which can be obtained in large quantities through an expression system, and the obtained mutant can be used as a biocatalyst. Compared with the wild-type enzyme VcUGT1, the yield of the product apigenin 7-O-glucoside can be increased by using apigenin as a substrate and UDP-glucose as a donor. Compared with the wild-type enzyme VcUGT1, the mutant of the present invention can efficiently utilize a variety of different types of glycosyl donors to generate corresponding glycoside products, such as using the flavonoid substance apigenin as a substrate acceptor, and can efficiently utilize UDP-glucose, UDP-galactose, UDP-N-acetylglucosamine and UDP-xylose to generate apigenin 7-O-glucoside, apigenin 7-O-galactoside, apigenin 7-ON-acetylglucosamine and apigenin 7-O-xyloside, respectively. Therefore, the mutant of the present invention can increase the diversity of flavonoid glycoside compounds, which is of great significance for the establishment of a natural drug library and drug screening. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 This is the plasmid map of pET32a-S14G-F366H-S367G;

[0021] Figure 2This is the SDS-PAGE electrophoresis result of pET32a-S14G-F366H-S367G recombinant Escherichia coli expression;

[0022] Figure 3 The results of high performance liquid chromatography (HPLC) of the wild type and mutant S14G-F366H-S367G using apigenin as substrate and UDP-glucose as donor;

[0023] Figure 4 The results of mass spectrometry analysis (LC / MS) of the wild type and mutant S14G-F366H-S367G using apigenin as substrate and UDP-glucose as donor;

[0024] Figure 5 The results of high performance liquid chromatography (HPLC) of the wild type and mutant S14G-F366H-S367G using apigenin as substrate and UDP-galactose as donor;

[0025] Figure 6 The results of mass spectrometry analysis (LC / MS) of the wild type and mutant S14G-F366H-S367G using apigenin as substrate and UDP-galactose as donor;

[0026] Figure 7 The results of high performance liquid chromatography (HPLC) of the wild type and mutant S14G-F366H-S367G using apigenin as substrate and UDP-N-acetylglucosamine as donor;

[0027] Figure 8 The results of mass spectrometry analysis (LC / MS) of the wild type and mutant S14G-F366H-S367G using apigenin as substrate and UDP-N-acetylglucosamine as donor;

[0028] Fig. 9 The results of high performance liquid chromatography (HPLC) of the wild type and mutant S14G-F366H-S367G using apigenin as substrate and UDP-xylose as donor;

[0029] Fig.10 The results of mass spectrometry analysis (LC / MS) of the wild type and mutant S14G-F366H-S367G using apigenin as substrate and UDP-xylose as donor. DETAILED DESCRIPTION

[0030] The present invention provides a glycosyltransferase VcUGT1 mutant, the amino acid sequence of which is shown in any one of the following: (a) SEQ ID No. 1: MSSHHHFLLLSCPGQGHLNPTLELAKKLTRADAHVTLATTVHGLRNITTLPAIENLSYATFSNGYDDGPDPTASYTVVMSEFKRVGSSTLTQLLTSLSTEGRPVTFLIYSILLPWAATVAREFHLPSAFLSIQSATSFAIYHSYFNTNNGLYPDKTTPPISIKLPGLPLFSSNEIPSFLLPDSPFVSVVPTFQEHIQTLEEDPNPVILANTFDELEQESIGAVD DMKVIPIGPLILSDRDPLQLNLFEKSTDYIQWLDSKPEKSVIYVSFGSMVVLQKKQIEEIFHGLLKTHRPFLWVIRKTEYQGEIKDLIETELNEEDGLIVPWCSQLEVLNHVST GCFLTHCGWNSVLESLVAGVPVVGLPQHGDQMTNVKMVEEVWGNGVRAAVNGEGVVEREEVGRCLEVVMGGGEKGEEIRRKCEKWKGLGKGAMVEGAQGGSSHKNLEQFLERLG;

[0031] (b) has more than 50% homology with (a), and the 14th amino acid is glycine (Gly), the 366th amino acid is histidine (His), and the 367th amino acid is glycine (Gly).

[0032]

[0033] The present invention provides a gene encoding the glycosyltransferase VcUGT1 mutant.

[0034] The present invention preferably uses a plasmid containing the gene encoding the glycosyltransferase VcUGT1 shown in SEQ ID No. 4 as a template and amplifies using the primers shown in Table 1 to introduce a point mutation.

[0035] Table 1 Primers used for cloning mutants

[0036] Primer name Primer sequence (5'-3') SEQ ID No. F366H-F cgcagCATgcggatcagatgactaa 5 F366H-R gatccgcATGctgcggcaaacccac 6 S367G-F cgcagcatGGCgatcagatgactaa 7 S367G-R ttagtcatctgatcGCCatgctgcg 8 S14G-F gccctGGCcaaggccacctcaacc 9 S14G-R ggccttgGCCagggcaggagaggag 10

[0037]

[0038] The present invention also provides biological materials comprising the above encoding gene.

[0039] The types of biomaterials described in the present invention preferably include recombinant expression vectors and recombinant expression hosts. The basic skeleton vector of the recombinant expression vector preferably includes a eukaryotic expression vector or a prokaryotic expression vector, and more preferably includes a pET series vector. In the embodiments, pET-32a is used as an example for illustration, but it cannot be identified as the entire protection scope of the present invention.

[0040] The host cell of the recombinant expression host of the present invention preferably includes bacterial cells, fungal cells or plant cells. In the embodiments, bacteria such as Escherichia coli are used for illustration, but they cannot be regarded as the only ones in the entire protection scope of the present invention.

[0041] The present invention also provides the use of the above biological material in preparing the above glycosyltransferase VcUGT1 mutant.

[0042] In a specific embodiment of the present invention, pET-32a is preferably used as an expression vector, the mutant nucleotide sequence shown in SEQ ID No. 2 is connected to the vector, and the constructed mutant plasmid is amplified in Escherichia coli Top10. The mutant plasmid is then extracted and transferred into Escherichia coli BL21 to express the mutant protein shown in SEQ ID No. 1, and then extracted and purified.

[0043] The present invention also provides the use of the glycosyltransferase VcUGT1 mutant prepared by using the above biological material in the in vitro enzyme-catalyzed production of flavonoid glycoside compounds.

[0044] The mutant of the present invention can be used as a catalytic enzyme, using apigenin as a substrate acceptor, to catalyze the glycosylation reaction of various glycosyl donors, thereby preparing various flavonoid glycoside compounds, greatly improving the breadth of flavonoid glycoside sugar donors, and providing a basis for the diversity of flavonoid glycoside compounds and their application in the field of biomedicine.

[0045] The present invention also provides a method for producing flavonoid glycoside compounds by enzyme catalysis in vitro, comprising taking apigenin as a substrate acceptor, utilizing the above-mentioned glycosyltransferase VcUGT1 mutant or the glycosyltransferase VcUGT1 mutant prepared by utilizing the above-mentioned biological material as an enzyme catalyst, catalyzing a glycosylation reaction of a glycosyl donor, and preparing flavonoid glycoside compounds.

[0046] The glycosyl donor of the present invention preferably includes at least one of the following: UDP-glucose, UDP-galactose, UDP-N-acetylglucosamine and UDP-xylose. The mutant of the present invention can efficiently utilize UDP-glucose, UDP-galactose, UDP-N-acetylglucosamine and UDP-xylose to generate apigenin 7-O-glucoside, apigenin 7-O-galactoside, apigenin 7-ON-acetylglucosamine and apigenin 7-O-xyloside, respectively.

[0047] The enzyme catalyzed reaction of the present invention preferably includes 50mM Tris-HCl buffer with pH=7.5 in 200μL, 20-50μg of mutant protein, 0.5mM final concentration of substrate apigenin, 1mM final concentration of sugar donor, 0.5mM CaCl2, preferably 25°C for 16h.

[0048] In order to further illustrate the present invention, a glycosyltransferase mutant provided by the present invention and its application in in vitro enzymatic production of various glycoside compounds are described in detail below in conjunction with the examples, but they should not be construed as limiting the scope of protection of the present invention.

[0049] Example 1 Obtaining glycosyltransferase mutants

[0050] 1. The glycosyltransferase mutant S14G-F366H-S367G is designed with wild-type glycosyltransferase pET32a-VcUGT1 plasmid from highbush blueberry as a template. The S14, F366, and S367 sites are mutated to obtain the mutant pET32a-S14G-F366H-S367G plasmid. The amplified mutant plasmid is then transformed into Escherichia coli Top10, positive clones are screened and tested, and recombinant engineered bacteria containing the pET32a-S14G-F366H-S367G plasmid are obtained.

[0051] (1) The wild-type glycosyltransferase VcUGT1 shown in SEQ ID No. 4 was inserted into the BamHI and XhoI sites of pET32a to construct the pET32a-VcUGT1 plasmid;

[0052] (2) Using the pET32a-VcUGT1 plasmid as a template, the serine at amino acid position 14 was first mutated to glycine using the full-form gold Fast Mutagenesis System kit. The primer sequences are shown in Table 1.

[0053] The PCR reaction system is as follows: 1ngpET32a-VcUGT1 plasmid, 25μL2×TransStart@FastPfu FlyPCRSuperMix, 1μL primer F (10μM), 1μL primer R (10μM), and fill to 50μL with ddH2O. The PCR amplification conditions are: pre-denaturation at 94℃, 3min; denaturation at 94℃, 20s; annealing, 55℃, 20s; extension at 72℃, 2min, a total of 25 cycles; complete extension at 72℃, 10min; storage at 4℃. After the PCR reaction is completed, 10μL of the amplified product is taken and detected by 1% agarose gel electrophoresis. If the target plasmid is correctly amplified, the next step of DMT digestion experiment can be carried out.

[0054] (3) DMT enzyme digestion, gel recovery and transformation of PCR products

[0055] 1 μL DMT enzyme was added to the remaining 40 μL PCR amplification product to digest the original template plasmid. The reaction conditions were 37°C for 1 h. Gel ExtractionKit agarose gel recovery kit, according to the instructions for gel recovery and purification of the digestion product. After the gel recovery product is detected by nanodrop, it is stored in a -20℃ refrigerator. Take 100μL Qingke Biocompetent Cell Top10 (TSC-C12) and melt it on ice, add 5μL of the purified digestion product, mix gently, let it stand on ice for 30min, 42℃ water bath for 60s, quickly transfer to an ice water bath, and let it stand for 5min. Add 800μL of LB medium without antibiotics and culture it at 37℃, 200rpm for 1h. Take about 100μL of bacterial solution and spread it on LB solid medium containing 50μg / mL ampicillin, and culture it at 37℃ for 12h. Pick 3 single colonies on the plate into LB medium (50μg / ml ampicillin), culture it at 37℃, 200rpm for 12h, and then take 1mL of bacterial solution from each plate and send it to Qingke Bio for sequencing. The successfully mutated pET32a-VcUGT1-S14G plasmid was used as a template to PCR amplify the F366H mutant using the same method, and so on. Figure 1 pET32a-VcUGT1-S14G-F366H-S367G mutant plasmid as shown.

[0056] Example 2 Expression and purification of glycosyltransferase mutants

[0057] The recombinant vector pET32a-VcUGT1-S14G-F366H-S367G plasmid constructed in Example 1 was chemically transformed into Escherichia coli BL21 competent cells. About 100 μL of the bacterial solution was spread on LB solid culture medium containing 50 μg / mL ampicillin and cultured at 37°C for 12 hours. A single colony on the plate was picked up and placed in 5 mL LB culture medium (50 μg / mL ampicillin) and cultured at 37°C, 200 rpm for 12 hours. Subsequently, it was transferred to 100 mL LB culture medium (50 μg / mL ampicillin) and cultured at 37°C, 200 rpm for 4 hours. When the OD 600 =0.7, add 10 μL of 1 M inducer IPTG, and induce culture at 16°C and 180 rpm for 18 h.

[0058] After the induction expression was completed, the bacterial solution was centrifuged at 4°C, 6000 rpm for 15 min to collect the bacteria. The bacteria were resuspended in PBS buffer and ultrasonically disrupted in an ice water bath. The supernatant was collected by centrifugation at 4°C, 12000 rpm for 20 min, and then filtered with a 0.45 μm water filter membrane and purified using a His-cobalt ion column affinity purification.

[0059] The purification steps are as follows: Take out the cobalt ion column refrigerated at 4°C, drain the preservation solution in the column, and use 20mL ddH2O to wash the cobalt ion column. First, use 10mL Equilibration Buffer to balance the column, then pass 20mL of the supernatant sample after passing the membrane through the column, and then use 8mL Equilibration Buffer and 15mL Wash buffer containing 15mM imidazole to wash the impurities in the column. Then, use 8mL Elution Buffer (containing 150mM imidazole) to elute the target protein, and use a 1.5mL centrifuge tube to collect small portions (numbered) 1-8. Use SDS-PAGE gel electrophoresis to verify the molecular weight of the purified protein ( Figure 2 ), and the concentration was determined using a BCA protein concentration detection kit. Finally, the protein was concentrated and desalted using a Millipore ultrafiltration tube, and an equal amount of 50% glycerol was added to each tube of pure protein, mixed, and stored at -80°C.

[0060] Example 3 Detection of the catalytic activity of wild-type enzyme VcUGT1 and mutant S14G-F366H-S367G on UDP-glucose

[0061] The catalytic activity of the wild-type enzyme VcUGT1 and its mutant S14G-F366H-S367G was tested in a 1.5 mL EP tube. The reaction system was: 50 mM Tris-HCl (pH 7.5), 0.5 mM CaCl2, 1 mM UDP-glucose, 0.5 mM apigenin, and finally 30 μg of pure enzyme was added, with a total volume of 200 μL. The reaction conditions were 25 ° C, 16 h. After the reaction was completed, an equal volume of methanol was added to terminate the reaction, and centrifuged at 12000 rpm for 30 min. The supernatant was collected and filtered with a 0.22 μm organic filter membrane for HPLC and LC / MS analysis.

[0062] HPLC detection method: The liquid chromatography column was Welch Ultimate LP-C18 column (250 mm × 4.6 mm, 5.0 μm). The mobile phase was methanol containing 0.1% formic acid (A) and 0.1% formic acid water (B). The gradient elution program was as follows: 0-1.5 min, 35% A; 1.5-7 min, 35-80% A; 7-12 min, 80% A, 12-13 min, 80-35% A; 13-17 min, 35% A. The detection wavelength was 290 nm, the flow rate was 1.0 mL / min, the column temperature was 30°C, and the sample injection volume was 20 μL.

[0063] LC / MS detection method: In order to further confirm the obtained product, an Agilent Q-TOF 6540 liquid chromatography-mass spectrometer (LC / MS) was used for detection. Mass spectrometry conditions: the ion source used the ion mode, voltage 3500V; fragmentation voltage: 175V; cone voltage: 65V; radio frequency voltage: 750V, range is negative ion mode (m / z 150-1200). Chromatographic conditions: the column used was a Welch Ultimate LP-C18 column (250mm×4.6mm, 5.0μm), flow rate 1.0ml / min. The mobile phase was methanol containing 0.1% formic acid (A) and 0.1% formic acid in water (B), and the gradient was 0-1.5 min, 35% A; 1.5-7 min, 35-80% A; 7-12 min, 80% A, 12-13 min, 80-35% A; 13-17 min, 35% A.

[0064] Depend on Figure 3 and Figure 4 It can be seen that the mutant S14G-F366H-S367G catalyzes apigenin to efficiently utilize UDP-glucoside to generate apigenin 7-O-glucoside (product a), with a conversion rate of 65%. The wild-type enzyme has a low utilization rate of UDP-glucose, with a conversion rate of about 6%. Compared with the wild-type, the mutant S14G-F366H-S367G has a higher utilization rate of UDP-glucose and a stronger catalytic activity.

[0065] Example 4 Detection of the catalytic activity of the wild-type enzyme VcUGT1 and the mutant S14G-F366H-S367G on UDP-galactose

[0066] The catalytic activity of the wild-type enzyme VcUGT1 and its mutant S14G-F366H-S367G was detected in a 1.5mL EP tube. The reaction system was: 50mM Tris-HCl (pH 7.5), 0.5mM CaCl2, 1mM UDP-galactose, 0.5mM apigenin, and finally 30μg of pure enzyme was added, with a total volume of 200μL. The reaction conditions were 25℃, 16h. After the reaction was completed, an equal volume of methanol was added to terminate the reaction, and centrifuged at 12000rpm for 30min. The supernatant was collected and filtered with a 0.22μm organic filter membrane for HPLC and LC / MS analysis.

[0067] The HPLC detection method and LC / MS detection method are as described in Example 3.

[0068] Depend on Figure 5 and Figure 6 It can be seen that the mutant S14G-F366H-S367G catalyzes apigenin to utilize UDP-galactose more efficiently to generate apigenin 7-O-galactoside (product b), with a conversion rate of 30%. The wild-type enzyme has no catalytic activity on UDP-galactose. Compared with the wild-type, the mutant S14G-F366H-S367G has a catalytic activity on UDP-galactose, which increases its sugar donor breadth.

[0069] Example 5 Detection of the catalytic activity of wild-type enzyme VcUGT1 and mutant S14G-F366H-S367G on UDP-N-acetylglucosamine

[0070] The catalytic activity of the wild-type enzyme VcUGT1 and its mutant S14G-F366H-S367G was detected in a 1.5 mL EP tube. The reaction system was: 50 mM Tris-HCl (pH 7.5), 0.5 mM CaCl2, 1 mM UDP-N-acetylglucosamine, 0.5 mM apigenin, and finally 30 μg of pure enzyme was added, with a total volume of 200 μL. The reaction conditions were 25 ° C, 16 h. After the reaction was completed, an equal volume of methanol was added to terminate the reaction, and centrifuged at 12000 rpm for 30 min. The supernatant was collected and filtered with a 0.22 μm organic filter membrane for HPLC and LC / MS analysis.

[0071] The HPLC detection method and LC / MS detection method are as described in Example 3.

[0072] Depend on Figure 7 and Figure 8It can be seen that the mutant S14G-F366H-S367G catalyzes apigenin to efficiently utilize UDP-N-acetylglucosamine to generate apigenin 7-ON-acetylglucosamine (product c), with a conversion rate of about 100%. The wild-type enzyme has no catalytic activity on UDP-N-acetylglucosamine.

[0073] Example 6 Detection of the catalytic activity of the wild-type enzyme VcUGT1 and the mutant S14G-F366H-S367G on UDP-xylose

[0074] The catalytic activity of the wild-type enzyme VcUGT1 and its mutant S14G-F366H-S367G was tested in a 1.5 mL EP tube. The reaction system was: 50 mM Tris-HCl (pH 7.5), 0.5 mM CaCl2, 1 mM UDP-xylose, 0.5 mM apigenin, and finally 30 μg of pure enzyme was added, with a total volume of 200 μL. The reaction conditions were 25 ° C, 16 h. After the reaction was completed, an equal volume of methanol was added to terminate the reaction, and centrifuged at 12000 rpm for 30 min. The supernatant was collected and filtered with a 0.22 μm organic filter membrane for HPLC and LC / MS analysis.

[0075] The HPLC detection method and LC / MS detection method are as described in Example 3.

[0076] Depend on Fig. 9 and Fig.10 It can be seen that the mutant S14G-F366H-S367G catalyzes apigenin to efficiently utilize UDP-xylose to generate apigenin 7-O-xylose (product d), with a conversion rate of about 85%. The wild-type enzyme has no catalytic activity on UDP-xylose. Compared with the wild-type, the mutant S14G-F366H-S367G has a catalytic activity on UDP-xylose, which increases its sugar donor breadth and the structural richness of related flavonoid glycoside compounds.

[0077] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.

Claims

1. A glycosyltransferase VcUGT1 mutant, characterized in that: The amino acid sequence is shown in any of the following: (a) SEQ ID No. 1; (b) has a homology of more than 50% with (a), and the 14th amino acid is glycine, the 366th amino acid is histidine, and the 367th amino acid is glycine.

2. The encoding gene of the glycosyltransferase VcUGT1 mutant according to claim 1.

3. The coding gene according to claim 2, characterized in that The coding gene includes the nucleotide sequence shown in SEQ ID No.

2.

4. A biological material comprising the coding gene according to claim 2 or 3.

5. The biomaterial according to claim 4, characterized in that: The types of biological materials include recombinant expression vectors and recombinant expression hosts.

6. The biomaterial according to claim 5, characterized in that: The basic skeleton vector of the recombinant expression vector includes a eukaryotic expression vector or a prokaryotic expression vector; The host cell of the recombinant expression host includes bacterial cells, fungal cells or plant cells.

7. Use of the biological material according to any one of claims 3 to 6 in the preparation of the glycosyltransferase VcUGT1 mutant according to claim 1.

8. Use of the glycosyltransferase VcUGT1 mutant prepared by using the biomaterial according to any one of claims 3 to 6 in the in vitro enzymatic production of flavonoid glycoside compounds.

9. A method for producing flavonoid glycoside compounds by in vitro enzyme catalysis, characterized in that: The method comprises taking apigenin as a substrate acceptor, utilizing the glycosyltransferase VcUGT1 mutant according to claim 1 or the glycosyltransferase VcUGT1 mutant prepared by utilizing any one of the biological materials according to claims 3 to 6 as an enzyme catalyst, catalyzing a glycosylation reaction of a glycosyl donor, and preparing flavonoid glycoside compounds.

10. The method according to claim 9, characterized in that: The glycosyl donor includes at least one of the following: UDP-glucose, UDP-galactose, UDP-N-acetylglucosamine and UDP-xylose.

Citation Information

Patent Citations

  • Genetically engineered bacterium for catalyzing glucose glycosylation of flavonoids compound and application thereof

    CN107164253A

  • Flavonoid glycosyl transferase as well as coding gene and application thereof

    CN115927240A

  • Application of glycosyl transferase mutant in catalytic synthesis of flavone glycoside compound

    CN118755685A

Cited By

  • Glycosyl hydrolase and application thereof in glucoside production

    CN120591226A

  • A glycosyl hydrolase and its use in the production of glycosides

    CN120591226B

  • The invention discloses glycosyltransferase, a gene segment, a recombinant expression vector, a recombinant bacterium, a preparation method and application of the recombinant bacterium, and flavonoid 3apos. Preparation method of-O-glucoside

    CN120699932A